grant
Computational and functional discovery of isoforms driving cancer and drug resistance
Organization UNIVERSITY OF CALIFORNIA SANTA CRUZLocation SANTA CRUZ, UNITED STATESPosted 14 Feb 2024Deadline 31 Jan 2029
NIHUS FederalResearch GrantFY2026AffectAllelesAllelomorphsAssayAutomobile DrivingB-raf-1BRAFBRAF geneBioassayBiologicalBiological AssayBiologyBiopsyC-K-RASCRISPRCRISPR/Cas systemCancer BiologyCancer DetectionCancer GenesCancer TreatmentCancer cell lineCancer-Promoting GeneCancersCell BodyCell LineCellLineCellsClinicalClustered Regularly Interspaced Short Palindromic RepeatsCodeCoding SystemCollaborationsCommunitiesCytogeneticsDNA mutationDataDevelopmentDideoxy Chain Termination DNA SequencingDrug resistanceEGF ReceptorEGFRERBB ProteinEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor KinaseEpidermal Growth Factor Receptor Protein-Tyrosine KinaseEpidermal Growth Factor-Urogastrone ReceptorsEventExonsExplosionGene AlterationGene ExpressionGene FusionGene MutationGenesGenetic ChangeGenetic EngineeringGenetic Engineering BiotechnologyGenetic Engineering Molecular BiologyGenetic defectGenetic mutationGenotypeHER1HeterogeneityHumanIn VitroIsoformsK-RAS2AK-RAS2BK-RasK-Ras 2AK-Ras-2 OncogeneKRASKRAS2KRAS2 geneKi-RASLengthLinkLung AdenocarcinomaLung NeoplasmsLung TumorMEKsMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMalignant Tumor of the LungMalignant neoplasm of lungMapsMass Photometry/Spectrum AnalysisMass SpectrometryMass SpectroscopyMass SpectrumMass Spectrum AnalysesMass Spectrum AnalysisMessenger RNAMethodologyMethodsModern ManMonitorMutateMutationNGS MethodNGS systemNon-Polyadenylated RNAORFsOncogene K-RasOncogenesOncogenesisOncogenicOpen Reading FramesOutcomePDX modelPathway interactionsPatient derived xenograftPatientsPeptidesPh 1 ChromosomePh1 ChromosomePhasePhenotypePhiladelphia ChromosomePositionPositioning AttributeProtein Coding RegionProtein IsoformsPublicationsPulmonary CancerPulmonary NeoplasmsPulmonary malignant NeoplasmRAFB1RASK2RNARNA Gene ProductsRNA ProcessingRNA SeqRNA SplicingRNA sequencingRNAseqRas InhibitorRecombinant DNA TechnologyResearch ResourcesResearch SpecimenResistanceResourcesRibonucleic AcidRoleSamplingSanger SequencingScientific PublicationSomatic MutationSpecimenSplicingStrains Cell LinesTCGATGF-alpha ReceptorTechnologyTestingThe Cancer Genome AtlasTranscriptTransforming GenesTransforming Growth Factor alpha ReceptorTumor Xenograft AssayUrogastrone ReceptorVariantVariationWorkXenograft Antitumor AssaysXenograft ModelXenograft Model Antitumor Assaysanti-cancer researchanti-cancer therapybiologicbiomarker drivenc-erbB-1c-erbB-1 Proteincancer biomarkerscancer carecancer genomicscancer markerscancer researchcancer therapycancer-directed therapycohortcultured cell linedevelopmentaldrivingdrug resistantdrug sensitivityerbB-1erbB-1 Proto-Oncogene ProteinerbBlexon skippingfunctional genomicsgene defectgene functiongenetically engineeredgenome annotationgenome mutationgenomic datagenomic datasetglobal gene expressionglobal transcription profilein vivoindividualized cancer careindividualized oncologyinhibitorinnovateinnovationinnovativeinsightkinase inhibitorlung cancermRNAmalignancymutantmutant alleleneoplasm/cancernext gen sequencingnext generation sequencingnextgen sequencingoncogenomicsoverexpressoverexpressionpathwaypatient derived xenograft modelpersonalization of treatmentpersonalized medicinepersonalized oncologypersonalized therapypersonalized treatmentpre-clinical trialprecision cancer careprecision cancer medicineprecision medicineprecision oncologyprecision-based medicinepreclinical trialprime editingprospectiveproto-oncogene protein c-erbB-1resistance mechanismresistance to Drugresistance to therapyresistantresistant mechanismresistant to Drugresistant to therapyresponsesocial rolesomatic varianttargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttechnological innovationtherapeutic resistancetherapy resistanttooltranscriptometranscriptome sequencingtranscriptomic sequencingtreatment resistancetumortumorigenesisv-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homologv-raf Murine Sarcoma Viral Oncogene Homolog B1xenograft transplant modelxenotransplant model
Get Agency plan to apply$29.99/mo · 7-day free trial · pipeline · alerts
or
— or —Get email alerts for similar roles
Description preview
ABSTRACT
A major challenge for the cancer genomics community is determining which somatic mutations are contributing
to tumorigenesis, which are “passenger” (neutral) mutations, and which mutations will inform personalized
treatment decisions. Unfortunately, most functional studies of cancer mutations have largely ignored the impact
of altered RNA…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click